Related Experiment Video
Updated: Aug 1, 2026

12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
Targeted glycemic reduction in critical care using closed-loop control
J Geoffrey Chase1, Geoffrey M Shaw, Jessica Lin
1Department of Mechanical Engineering, Centre for Bio-Engineering, University of Canterbury, Christchurch, New Zealand. geoff.chase@canterbury.ac.nz
Diabetes Technology & Therapeutics
|April 29, 2005
Summary
An adaptive glucose control protocol for critically ill patients achieves tight glycemic regulation, improving upon fixed methods. This new system accounts for individual patient dynamics, reducing errors and enhancing patient outcomes.
Area of Science:
- Physiological modeling
- Biomedical engineering
- Critical care medicine
Background:
- Critically ill patients frequently experience hyperglycemia, posing challenges for standard glucose management protocols.
- Existing fixed protocols and sliding scales often lead to errors and suboptimal glycemic control in diverse patient populations.
- Tight glucose control is crucial for reducing mortality in critical care settings.
Observation:
- A physiologically based two-compartment model was developed, incorporating time-varying insulin sensitivity and glucose removal.
- An adaptive, bolus-based control protocol was designed to monitor patient status for precise glycemic regulation.
- Preliminary proof-of-concept clinical trials were conducted over 5 hours each.
Findings:
- The adaptive protocol achieved preset glycemic targets with an average absolute error of 9%.
- 75% of glycemic targets were met within the 7% measurement error margin.
- Observed errors exceeding 7% ranged from 17% to 21%.
Implications:
- The adaptive system demonstrated tight stepwise glycemic control, aligning with patient dynamics.
- Errors were often linked to external factors like drug therapies, suggesting areas for protocol refinement.
- This approach offers targeted, stepwise tight glycemic regulation through insulin boluses in critical care.
Related Concept Videos
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...
Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Hypoglycemia and Glucagon
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
Hypoglycemia
Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...

